Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort

@article{Purhonen2012OutcomeOP,
  title={Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort},
  author={Maija Purhonen and Hannu Koponen and Jari Tiihonen and Antti O. Tanskanen},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2012},
  volume={21}
}
Thioridazine is a first‐generation antipsychotic drug that was withdrawn from the market worldwide in 2005. The outcome of clinically stable schizophrenia patients who used thioridazine before market withdrawal was evaluated. 
20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
TLDR
Evidence is provided that, contrary to general belief, the risk of treatment failure or relapse after discontinuation of antipsychotic use does not decrease as a function of time during the first 8 years of illness, and that long-term antipsychotics treatment is associated with increased survival.
De novo treatment-resistant psychosis following thioridazine withdrawal
TLDR
A presentation of thioridazine withdrawal treatment-resistant psychosis in an intellectually impaired patient without a history of psychosis is described, verified by the review of the existing literature.
Consequences of market withdrawal of fluphenazine and trifluoperazine: Letter to the editor and case series
  • J. Zanker, A. Ferraro
  • Psychology, Medicine
    The Australian and New Zealand journal of psychiatry
  • 2017
TLDR
A case series of nine patients admitted to an acute facility within a metropolitan mental health area network from February to May 2017, identifying an important, contemporaneous public health issue following cessation of fluphenazine or trifluoperazine.
Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach
TLDR
Clinical guidance on the following adverse effects and antipsychotics was reviewed: electrocardiogram (ECG) changes, weight gain, dyslipidemia, metabolic syndrome, and myocarditis.
Psychoactive prescribing for older people—what difference does 15 years make?
The objective of the study was to review prescribing of psychoactive medications for older residents of the Tayside region of Scotland.
Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
TLDR
Investigating the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation during 2006–2009 found the low rate of discontinuation is consistent with the Finnish Care Guideline but in contrast to the results reported from many other countries.
Antipsychotics and Electrocardiographic monitoring in patients with Schizophrenia.
TLDR
The ECG monitoring in the study patients was inadequate, and as a result, it was unable to evaluate the prevalence of prolonged QTc interval with confidence, and recommends performing baseline ECGs for these patients and conducting ECG teachings for clinicians who work in the psychiatric service settings.
Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study
TLDR
Long-term use of antipsychotics is frequent among community-dwelling persons with Alzheimer׳s disease (AD) during a 7-year follow-up and duration of use is not in line with the guidelines recommending time-limited use.
Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland
TLDR
Clinicians should regularly assess dosing levels especially among men and those with history of psychiatric disorder, which indicates a need for precise dosing instructions in the treatment of behavioral and psychological symptoms of dementia.
Concomitant Use of Acetylcholine Esterase Inhibitors and Urinary Antispasmodics Among Finnish Community-Dwelling Persons With Alzheimer Disease
TLDR
It is recommended to consider some other options than UAs to treat urinary incontinence among persons with AD and the duration of concomitant use was comparatively long.
...
1
2
3
...

References

SHOWING 1-10 OF 17 REFERENCES
[Repercussions of the withdrawal of thioridazine].
TLDR
A high cost in terms of care, economic resources and of quality of life (autonomy, social skills and cognitive level) in the authors' sample as a result of Meleril (thioridazine) withdrawal of the market is demonstrated.
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
TLDR
Although the proportional use of second-generation antipsychotic drugs rose from 13% to 64% during follow-up, the gap in life expectancy between patients with schizophrenia and the general population did not widen between 1996 and 2006.
Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs
TLDR
It is argued that directives should take greater account of the risks associated with changing successfully established drug regimens, especially in vulnerable populations such as people with learning disabilities, after guidelines relating to thioridazine were revised.
Olanzapine versus haloperidol in the treatment of first episode psychosis
TLDR
The study results suggest that novel antipsychotic agents such as olanzapine should be considered as a preferred option in first-episode psychosis, on the basis of both safety and efficacy advantages.
Thioridazine and sudden unexplained death in psychiatric in-patients.
TLDR
Thioridazine alone was associated with sudden unexplained death, the likely mechanism being drug-induced arrhythmia, and there was no significant association with other individual antipsychotic drugs.
A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
TLDR
It is suggested that quetiapine may make a valuable contribution to the management of patients with a history of partial response to conventional antipsychotics, as shown in the results of this international, multicentre, double‐blind study.
Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics.
  • P. Bech, J. Peuskens, +5 authors A. Claus
  • Psychology, Medicine
    European psychiatry : the journal of the Association of European Psychiatrists
  • 1998
TLDR
R risperidone is a more effective antipsychotic than the conventional agents and causes less severe extrapyramidal symptoms.
Iatrogenic Disorders Associated with Conventional vs. Atypical Antipsychotics
  • H. Nasrallah, T. Mulvihill
  • Medicine
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2001
TLDR
The second-generation (atypical) antipsychotics, introduced 40 years after the advent of the older-generation, are proving to have better outcomes in psychosis not only because of broader symptom efficacy but also because their side-effect profile is more tolerable, leading to higher compliance and fewer relapses.
Partial compliance in schizophrenia and the impact on patient outcomes
  • P. Llorca
  • Psychology, Medicine
    Psychiatry Research
  • 2008
TLDR
It is demonstrated that partial compliance with antipsychotic medication is a significant barrier to achieving optimal outcomes in schizophrenia, and long-acting risperidone may therefore bring together the benefits of the atypical antipsychotics with the long- acting injection delivery system required to build a platform for improved outcomes.
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
TLDR
Antipsychotic drugs cause QTc lengthening in a dose-related manner, and risks are substantially higher for thioridazine and droperidol, which may confer an increased risk of drug-induced arrhythmia.
...
1
2
...